Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. September 2025 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a...
22. Oktober 2013 12:44 ET | Quelle: abas-USA

abas-USA Announces New On-Site Training Facility

STERLING, VA--(Marketwired - Oct 22, 2013) - abas-USA is pleased to announce they will be moving and expanding their East Coast headquarters in November. The new facility will accommodate future...